---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-010031"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:28:50.980410+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# MetaVia partners with Syntekabio to use AI for new DA-1241 indications

## Summary
- Collaboration leverages Syntekabio’s DeepMatcher platform to screen >1,700 protein targets for new DA-1241 indications.
- Follows positive Phase 2a data in MASH; DA-1241 showed safety, hepatoprotective, and glucose-regulating effects.
- No financial terms disclosed; initial insights expected later in 2025.
- DA-1241 is a novel oral GPR119 agonist in clinical development for cardiometabolic diseases.

## SEC filing metadata
- accession: 0001558370-25-010031
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837025010031/0001558370-25-010031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837025010031/mtva-20250804x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-010031
- JSON: https://secwatch.observer/filing/0001558370-25-010031.json
- Plain text: https://secwatch.observer/filing/0001558370-25-010031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.